title: [The evolution of threshold values of air conduction in the extended high frequency range (9-18 kHz) in patients suffering from the pulmonary tuberculosis treated with combination of SM, INH, RFM, and PZA].
abstract: The evolution of threshold values of air conduction in the extended high frequency range (9-18 kHz) at patients suffering from the active pulmonary tuberculosis treated with the combined therapy (SM, INH, RFM, PZA). There were audiologically examined 13 patients (the average age 41.2) suffering from the active pulmonary tuberculosis and treated with the combined therapy (SM, INH, RFM, PZA). In 13 tuberculosis patients the full range of audiometric tests and measurements including: the pure tone audiometry, acoustic impedance and the extended high frequency range threshold audiometry (9-18 kHz) have been applied before starting the treatment with SM, INH, RMP and PZA and in the two months later--after its completion. The reference group was composed of 10 audiologically healthy individuals (the average age 40.2). A significant hearing loss with respect to air conduction within the extended range of high frequencies (9-17 kHz) was stated. The said hearing pathology can be diagnosed at earlier stages by the use of the extended high frequency range audiometry than through applying methods of conventional audiometry.
authors.affiliation: Katedry i Kliniki Laryngologii Slaskiej A.M. w Katowicach.
authors.forename: Tatiana
authors.initials: T
authors.lastname: Gierek
authors.forename: Jarosław
authors.initials: J
authors.lastname: Markowski
authors.forename: Jolanta
authors.initials: J
authors.lastname: Kieda-Szurkowska
authors.forename: Jarosław
authors.initials: J
authors.lastname: Paluch
authors.forename: Ireneusz
authors.initials: I
authors.lastname: Bielecki
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects*; D001301:Audiometry, Pure-Tone; D001309:Auditory Threshold; D016022:Case-Control Studies; D003638:Deafness / Q000139:chemically induced*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007538:Isoniazid / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D011044:Poland; D011718:Pyrazinamide / Q000009:adverse effects; D012293:Rifampin / Q000009:adverse effects; D013307:Streptomycin / Q000009:adverse effects; D014397:Tuberculosis, Pulmonary / Q000150:complications / Q000188:drug therapy*
chemical_list: D000995:Antitubercular Agents; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin